Resonetics acquires manufacturing assets, process IP from Med-Ally

The acquisition expands Resonetics’ bioelectronics implant offering, combining its implantable battery technologies with advanced pulse generator manufacturing processes.

Text reading M&A Mergers and Acquisitions

AdobeStock | 122587477-onephoto

Resonetics has acquired the manufacturing assets, process know-how, and intellectual property related to implantable and external pulse generators (IPG/EPG) and leads manufacturing and assembly from Med-Ally, a medical technology design and development company focused on the neuromodulation market and based in Charleston, South Carolina.

The acquisition strengthens Resonetics' Medical Power business by combining its comprehensive implantable battery technologies with advanced pulse generator manufacturing processes. This integration enables Resonetics to offer customers another critical solution, from energy source to active implantable device, serving the expanding neuromodulation, brain-computer-interface (BCI), and cardiac rhythm management (CRM) markets. As part of the deal, the acquired assets will ultimately be transferred to an existing Resonetics facility.

"This acquisition represents an important step forward for our Bioelectronic market segment," says Kevin Kelly, CEO of Resonetics. "We already provide implantable batteries that power neurostimulation and cardiac devices. Now we can manufacture the pulse generators themselves, giving customers a more integrated and efficient solution."

"Combining IPG manufacturing & assembly with Resonetics' implantable battery expertise creates a differentiated capability in the industry," adds Fred Borne, VP of Fiber Optic Sensors & Medical Power at Resonetics. "We're now positioned to be the comprehensive partner for next-generation neuromodulation devices, something our customers have been seeking."

The acquisition marks the third notable transaction for Resonetics in the last twelve months, having added nitinol gun-drilling and insert- and micro-molding with the prior acquisitions of select assets from Medical Component Specialists and Eden Holdings.  The company will continue to target niche manufacturing technologies that support its focus on the most innovative market segments within the medical device industry.